Innovative Research Award
Harry Bear
Virginia Commonwealth University, United States
Harry Bear is a surgical oncologist and academic researcher affiliated with Virginia Commonwealth University, where his work encompasses breast cancer, tumor immunology, immunotherapy, translational research, and clinical trials. Institutional records describe his academic appointments and research leadership within surgical oncology and the Massey Cancer Center. The Innovative Research Award recognizes researchers whose sustained scholarly activity contributes to scientific advancement through original research, interdisciplinary collaboration, and measurable research impact.[1][2]
Abstract
Harry Bear’s academic profile reflects a long-standing research program in surgical oncology, breast cancer, tumor immunology, and translational clinical research. Virginia Commonwealth University identifies him as a Professor in the Division of Surgical Oncology and Professor of Surgery and Microbiology and Immunology, with research interests including T-cell biology, immunotherapy, breast cancer treatment trials, and translational clinical research.[1] His ORCID record also documents research publications involving breast cancer treatment, immune checkpoint inhibition, neoadjuvant therapy, and related oncology research.[2]
Keywords
Oncology, Surgical Oncology, Breast Cancer, Cancer Immunology, Tumor Immunology, Cancer Immunotherapy, T-Cell Biology, Translational Research, Clinical Trials, Neoadjuvant Therapy, Breast Cancer Research, Innovative Research Award.
Introduction
Modern oncology increasingly integrates surgical treatment, molecular biology, immunology, systemic therapies, and clinical trial methodologies. Research in these areas seeks to improve treatment selection, understand mechanisms of tumor progression and immune response, and translate laboratory findings into clinically relevant therapeutic strategies. Harry Bear’s research career has included work across these interconnected areas, particularly breast cancer and cancer immunology.[1]
Institutional information indicates that Bear has contributed to breast cancer clinical research and has held leadership roles associated with clinical trials and oncology research. His work has included both preclinical and clinical investigations, providing a translational connection between experimental immunology and patient-oriented oncology research.[1][3]
Research Profile
Harry Bear is affiliated with Virginia Commonwealth University and the Massey Cancer Center. VCU describes his clinical interests as including breast cancer and other breast diseases, melanoma, sarcoma, and gastrointestinal cancers. His research interests include basic tumor immunology, T-cell biology, immunotherapy, translational clinical research, and breast cancer treatment trials.[1]
- Affiliation: Virginia Commonwealth University.
- Primary subject area supplied for the award profile: Oncology.
- Research themes: breast cancer, tumor immunology, T-cell biology, immunotherapy, and translational oncology.
- Research activity includes preclinical investigations and clinical trials.
The supplied bibliometric profile records 201 documents, 15,996 citations, and an h-index of 49. These figures are presented as the supplied research-profile metrics and should be interpreted in conjunction with the underlying indexing database and its date of retrieval.[4]
Research Contributions
Bear’s research contributions are centered on the interaction between cancer biology, immune mechanisms, and clinical treatment strategies. VCU records describe his work in preclinical and clinical studies of immunotherapy and breast cancer treatment trials, while his institutional profile notes extensive involvement in national cooperative oncology research.[1]
- Research into tumor immunology and T-cell biology.
- Development and evaluation of cancer immunotherapy strategies.
- Translational research connecting laboratory findings with clinical oncology.
- Participation in breast cancer clinical trials and cooperative oncology research.
- Research addressing treatment strategies for breast cancer and other malignancies.
Examples in the ORCID record include research on immune checkpoint inhibition combined with hypomethylation for locally advanced HER2-negative breast cancer, as well as studies of treatment strategies in high-risk hormone receptor-positive and HER2-negative breast cancer.[2]
Publications
The documented publication record includes peer-reviewed studies addressing breast cancer treatment, immunotherapy, tumor-induced immune mechanisms, and clinical trial outcomes. ORCID lists, among other works, the 2025 Journal for ImmunoTherapy of Cancer article on T-cell immune checkpoint inhibition and hypomethylation, the 2025 Annals of Oncology report of final PENELOPE-B survival results, and earlier research on neoadjuvant therapy and breast cancer treatment selection.[2]
- Cancer immunotherapy and immune checkpoint research.
- Breast cancer clinical and translational research.
- Neoadjuvant treatment research.
- Clinical trial outcome analysis.
Selected DOI-indexed publications associated with Harry D. Bear include T-cell immune checkpoint inhibition plus hypomethylation for locally advanced HER2-negative breast cancer, DOI 10.1136/jitc-2024-010294, and Final survival results from the PENELOPE-B trial, DOI 10.1016/j.annonc.2025.03.010.[2]
Research Impact
The supplied citation and h-index figures indicate substantial scholarly visibility, while institutional records document a sustained role in cancer research and clinical trial activity. VCU reports that Bear has authored more than 190 articles and book chapters and has contributed to national cooperative oncology research organizations.[1] The research portfolio therefore combines bibliometric productivity with clinical and translational relevance.
His research has also contributed to investigations of cancer immunotherapy and immune-cell biology. VCU reports collaborative work examining methods for improving immune-cell responses against cancer, while the National Cancer Institute lists Harry Bear as a member of its Breast Immuno-Oncology Task Force.[3][5]
Award Suitability
The available academic evidence provides several factors relevant to consideration for an Innovative Research Award. These include sustained research activity, a substantial publication record, significant citation visibility, contributions to cancer immunology and immunotherapy, and participation in clinical and translational research. VCU’s institutional profile additionally documents prior recognition for contributions to clinical care, service, and innovative research.[1]
The supplied profile identifies the associated event as the International Soil Scientist Awards. Because the researcher’s documented subject area is Oncology, the academic evidence presented on this page supports evaluation of the researcher primarily on the basis of oncology research and innovation rather than soil science. Final award eligibility and selection remain subject to the official criteria and review procedures of the organizing body.
Conclusion
Harry Bear’s research profile reflects sustained activity in surgical oncology, breast cancer, tumor immunology, immunotherapy, and translational clinical research. His institutional record, documented publications, ORCID-linked research outputs, and supplied bibliometric indicators collectively provide a substantial academic basis for consideration under an innovative research recognition category.[1][2]
External Links
References
- Virginia Commonwealth University Health. (n.d.). Harry Bear, MD, PhD — VCU Health.
https://www.vcuhealth.org/find-a-provider/profile/harry-bear
- ORCID. (n.d.). ORCID record: Harry Bear, ORCID iD 0000-0002-7632-9019. The record includes publications and DOI-linked research outputs in oncology.
https://orcid.org/0000-0002-7632-9019
- Virginia Commonwealth University. (n.d.). Surgical Oncology — Department of Surgery. Virginia Commonwealth University School of Medicine.
https://surgery.vcu.edu/divisions/surgical-oncology/index.html
- Elsevier. (n.d.). Scopus author details: Harry Bear, Author ID 7006222793. Scopus.
https://www.scopus.com/pages/authors/7006222793
- National Cancer Institute. (n.d.). Breast Cancer Steering Committee Task Force Rosters. National Cancer Institute. Harry Bear, M.D., Ph.D., is listed as a member of the Breast Immuno-Oncology Task Force.
https://www.cancer.gov/about-nci/organization/ccct/steering-committees/nctn/breast-cancer/task-force-rosters